Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 6/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.41 |
| ▸ | TGM2 | P21980 | 5/20 | 0.39 |
| ▸ | F13A1 | P00488 | 3/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.39 |
| ▸ | TGM1 | P22735 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4137206 | 0.82 | STS (0.50) | STSMAPTTACR1TGFBR1GPR119 | |
| SCHEMBL2916404 | 0.78 | STS (0.55) | STSMAPTTACR1TGFBR1TGM2 | |
| SCHEMBL2920158 | 0.77 | STS (0.62) | STSTACR1TGFBR1GPR119SCN9A | |
| SCHEMBL2921629 | 0.76 | STS (0.53) | STSMAPTTACR1TGFBR1GPR119 | |
| SCHEMBL4131323 | 0.76 | STS (0.43) | STSMAPT | |
| SCHEMBL7803789 | 0.72 | KDM4E (0.69) | STSTACR1TGFBR1GPR119 | |
| SCHEMBL2952898 | 0.72 | STS (1.00) | STSTACR1TGFBR1 | |
| SCHEMBL23217017 | 0.71 | STS (0.54) | STSMAPTTACR1GPR119 | |
| SCHEMBL447435 | 0.71 | STS (0.49) | STSMAPTTACR1GPR119 | |
| SCHEMBL8662177 | 0.71 | USP2 (0.58) | MAPTGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042899-A1 | Piperazinyl-or piperidinylamine-sulfamic acid amides as inhibitors of steroid sulfatase | LEHR PHILIPP | 2009-02-12 | — | — | US | disclosed |
| US-7439362-B2 | Piperazinyl-or piperidinylamine-sulfamic acid amides as inhibitors of steroid sulfatase | NOVARTIS AG (CH) | 2008-10-21 | — | — | US | disclosed |
| US-20060052393-A1 | Piperazinyl-or piperidinylamine-sulfamic acid amides as inhibitors of steroid sulfatase | NOVARTIS AG (CH) | 2006-03-09 | — | — | US | disclosed |
| EP-1492782-A1 | PIPERAZINYL- OR PIPERIDINYLAMINE-SULFAMIC ACID AMIDES AS INHIBITORS OF STEROID SULFATASE | Novartis AG (CH) | 2005-01-05 | — | — | EP | disclosed |
| WO-2003082842-A1 | PIPERAZINYL- OR PIPERIDINYLAMINE-SULFAMIC ACID AMIDES AS INHIBITORS OF STEROID SULFATASE | NOVARTIS AG (CH) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042899-A1 | Piperazinyl-or piperidinylamine-sulfamic acid amides as inhibitors of steroid sulfatase | STS, SULT2A1, ARSA | STS 1/4885MAPT 4253/4885TACR1 1098/4885 |
| US-20060052393-A1 | Piperazinyl-or piperidinylamine-sulfamic acid amides as inhibitors of steroid sulfatase | STS, SELENOI, SULT2A1 | STS 1/4885MAPT 4507/4885TACR1 1430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.